Evaluation of Vaccine Strategies Among Healthcare Workers During COVID-19 Omicron Outbreak in Taiwan

Overview

Journal Vaccines (Basel)

Date 2024 Sep 28

PMID 39340088

Authors

Min-Ru Lin

Chung-Guei Huang

Cheng-Hsun Chiu

Chih-Jung Chen

Affiliations

Soon will be listed here.

Abstract

Background/objectives: This study aimed to assess the reactogenicity and immunogenicity of various SARS-CoV-2 vaccines and compare their protective effects against COVID-19 among healthcare workers (HCWs) during the Omicron outbreak in Taiwan.

Methods: Conducted from March 2021 to July 2023, this prospective observational study included healthy HCWs without prior COVID-19 immunization. Participants chose between adenovirus-vectored (AstraZeneca), mRNA (Moderna, BioNTech-Pfizer), and protein-based (Medigen, Novavax) vaccines. Blood samples were taken at multiple points to measure neutralizing antibody (nAb) titers, and adverse events (AEs) were recorded via questionnaires.

Results: Of 710 HCWs, 668 (94.1%) completed three doses, and 290 (40.8%) received a fourth dose during the Omicron outbreak. AEs were more common with AstraZeneca and Moderna vaccines, while Medigen caused fewer AEs. Initial nAb titers were highest with Moderna but waned over time regardless of the vaccine. Booster doses significantly increased nAb titers, with the highest levels observed in Moderna BA1 recipients. The fourth dose significantly reduced COVID-19 incidence, with Moderna BA1 being the most effective.

Conclusions: Regular booster doses, especially with mRNA and adjuvant-protein vaccines, effectively enhance nAb levels and reduce infection rates, providing critical protection for frontline HCWs during variant outbreaks.

References

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Gebru A, Birhanu T, Wendimu E, Ayalew A, Mulat S, Abasimel H . Global burden of COVID-19: Situational analyis and review. Hum Antibodies. 2020; 29(2):139-148. DOI: 10.3233/HAB-200420. View

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

Collie S, Champion J, Moultrie H, Bekker L, Gray G . Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2021; 386(5):494-496. PMC: 8757569. DOI: 10.1056/NEJMc2119270. View

Lyke K, Atmar R, Dominguez Islas C, Posavad C, Szydlo D, Paul Chourdhury R . Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022; 3(7):100679. PMC: 9212999. DOI: 10.1016/j.xcrm.2022.100679. View

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

Lai C, Ko W, Chen C, Chen P, Huang Y, Lee P . COVID-19 vaccines and thrombosis with thrombocytopenia syndrome. Expert Rev Vaccines. 2021; 20(8):1027-1035. DOI: 10.1080/14760584.2021.1949294. View

Atmar R, Lyke K, Deming M, Jackson L, Branche A, El Sahly H . Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022; 386(11):1046-1057. PMC: 8820244. DOI: 10.1056/NEJMoa2116414. View

10.

Mannar D, Saville J, Zhu X, Srivastava S, Berezuk A, Tuttle K . SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 2022; 375(6582):760-764. DOI: 10.1126/science.abn7760. View

11.

Kwon D . Omicron's molecular structure could help explain its global takeover. Nature. 2022; 602(7897):373-374. DOI: 10.1038/d41586-022-00292-3. View

12.

Hsieh S, Liu M, Chen Y, Lee W, Hwang S, Cheng S . Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir Med. 2021; 9(12):1396-1406. PMC: 8514195. DOI: 10.1016/S2213-2600(21)00402-1. View

13.

Paterlini M . Covid-19: Sweden, Norway, and Finland suspend use of Moderna vaccine in young people "as a precaution". BMJ. 2021; 375:n2477. DOI: 10.1136/bmj.n2477. View

14.

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

15.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

16.

Tian D, Sun Y, Xu H, Ye Q . The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol. 2022; 94(6):2376-2383. PMC: 9015498. DOI: 10.1002/jmv.27643. View

17.

Wall E, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C . Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021; 397(10292):2331-2333. PMC: 8175044. DOI: 10.1016/S0140-6736(21)01290-3. View

18.

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

19.

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C . Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25(12):1822-1832. PMC: 7147972. DOI: 10.1038/s41591-019-0675-0. View

20.

Heath P, Galiza E, Baxter D, Boffito M, Browne D, Burns F . Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021; 385(13):1172-1183. PMC: 8262625. DOI: 10.1056/NEJMoa2107659. View